<div id="readability-page-1"><div><p>China's Supreme People's Court has upheld the validity of the substance patent for semaglutide, thereby confirming a previous ruling from the Beijing IP Court.</p><p>  The decision strengthens Novo Nordisk's intellectual property rights in the world's second-largest economy. </p><p>  &#34;This outcome is very positive for semaglutide and demonstrates strong government support for protecting medical innovation,&#34; said Mike Doustdar, CEO of Novo Nordisk. </p><p>  &#34;The decision also boosts confidence in the sustainable development of foreign companies in China and will encourage further development and introduction of innovative medicines for the benefit of patients.&#34; </p><p>The company stated that the ruling does not change previous communications regarding patent expirations or forecasts. No financial details were disclosed.</p></div></div>

諾和諾德公司

<p>中國最高人民法院維持了諾和諾德公司的賽美特（semaglutide）專利，強化了該公司的知識產權。首席執行官 Mike Doustdar 表示，這一裁決支持了醫療創新，並增強了外國公司在中國的信心，鼓勵創新藥物的發展。該裁決並未改變之前關於專利到期或預測的溝通，也沒有提供財務細節</p>

中國法院維持了諾和諾德公司的專利權